Lignan complex derived from flaxseed as hypercholesterolemic and anti-atherosclerotic agent

Inactive Publication Date: 2009-07-07
ARCHER DANIELS MIDLAND CO
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011]When administered to humans or non-human animals, the complex has been found to be highly effective for treating hypercholesterolemic atherosclerosis, as well as for reducing total cholesterol and raising HDL-C in blood. Thus, it is useful for the prevention and treatment of coronary artery disease, stroke and other peripheral vascular diseases.

Problems solved by technology

Drugs used for lowering serum lipids and for treatment of atherosclerosis (heart attack and stroke) have many side effects and are expensive.
However, isolating SDG from flaxseed is a relatively expensive procedure.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lignan complex derived from flaxseed as hypercholesterolemic and anti-atherosclerotic agent
  • Lignan complex derived from flaxseed as hypercholesterolemic and anti-atherosclerotic agent
  • Lignan complex derived from flaxseed as hypercholesterolemic and anti-atherosclerotic agent

Examples

Experimental program
Comparison scheme
Effect test

example 1

EXPERIMENTAL PROTOCOL

[0037]Experiments were conducted on New Zealand White rabbits. Rabbits were assigned to 4 groups as shown in Table 1. Those in Group 1 were fed rabbit laboratory chow diet. The other groups received lignan complex or cholesterol or cholesterol+lignan complex. The lignan complex was obtained from Agriculture and Agri-Food Canada and was extracted from flaxseed by the method described in Westcott et al., U.S. Pat. No. 6,264,853incorporated herein by reference. The diet was especially prepared by Purina and did not contain any antioxidant. Lignan complex was given orally daily in the dose of 40 mg / kg body weight. The rabbits were cared for according to approved standards for laboratory animal care. The rabbits were on their respective diet treatment for 2 months.

[0038]Blood samples were collected (from ear marginal artery) for measurement of serum-triglycerides (TG), total cholesterol. (C), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein chole...

example 2

[0051]Studies were conducted to determine if the lignan complex given for 2 months produces adverse effects on liver and kidney function.

[0052](a) Assessment of liver function was made by measuring serum enzymes [alkaline phosphatase (ALP), alanine amino-transferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT)] and serum albumin. These serum enzymes are elevated and serum albumin is decreased in liver disease. The results are summarized in Table 15-19. Serum levels of ALT, AST and GGT were similar in Groups I and II at month two of the protocol, however levels of serum ALP were lower in Group II compared to Group I. The changes in the serum levels of ALP, ALT and GGT remained unchanged as compared to “0” month in the Groups III and IV. However serum levels of AST increased to a similar extent in both groups III and IV. Serum albumin levels increased at month one as compared to “0” month in all the groups, however the increases at month two were not sig...

example 3

[0057]The lignan complex was also fed orally to normal ratsfor 2 months at a daily dosage of 40 mg / kg of body weight and the rats were studied to see if the complex had any affect on the liver and kidney function and hemopoietic cells. It was found that the lignan complex did not affect any of the above, indicating that it is not toxic to liver, kidney and blood cells.

[0058]

TABLE 1Experimental Diet GroupsGroupDiet / TreatmentI (n = 10)Control (Rabbit chow diet)II (n = 6)Lignan complex control (Rabbit chow dietsupplemented with lignan complex, 40 mg / kg bodyweight, orally, daily)III (n = 12)Cholesterol diet (0.5% cholesterol in rabbit chowdiet)IV (=16)Cholesterol diet + lignan complex (0.5%cholesterol diet supplemented with lignan complex,40 mg / kg; body weight, orally, daily)

[0059]

TABLE 2Red Blood Cells (RBC) Counts (1012 / L) in theExperimental Groups Time (months)Group012I. Control diet5.08 ± 0.12  6.22 ± 0.18* 6.04 ± 0.16*   II. Control diet +5.76 ± 0.16a6.03 ± 0.13   5.90 ± 0.20   lig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Weightaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

A method is described for treating hypercholesterolemic atherosclerosis or for reducing total cholesterol while raising high-density lipoportoein cholesterol. It involves administering to a patient a substantially pure complex derived from flaxseed and containing secoisolariciresinol diglucoside (SDG), cinnamic acid glucosides and hydroxymethyl glutaric acid.

Description

BACKGROUND OF THE INVENTION[0001]1. Field of the Invention[0002]This invention relates to a method for the use of a lignan complex isolated from flaxseed for the treatment of atherosclerosis, e.g. reducing or preventing the development of hypercholesterolemic atherosclerosis, for reducing total cholesterol and for raising HDL-C in blood.[0003]2. Description of the Prior Art[0004]Hypercholesterolemia is a major risk factor for atherosclerosis (narrowing of the artery due to deposition of fat in the arterial wall) and related occlusive vascular diseases such as heart attack, stroke and other peripheral vascular diseases. Heart disease is the number one killer. Hypercholesterolemic atherosclerosis has been reported to be associated with oxidative stress increase in levels of reactive oxygen species (ROS), production of ROS by polymorphonuclear leukocytes as assessed by chemiluminescence (PMNL-CL), and a decrease in the antioxidant reserve. Pretreatment with antioxidants (vitamin E, pro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07H15/00A61K31/19A61K31/70A61K51/12
CPCA61K31/19A61K31/70A61K51/1206
InventorPRASAD, KAILASH
OwnerARCHER DANIELS MIDLAND CO